Mayo Clinic researchers find that stem cells with the highest Myc expression become dominant in driving lung remodeling .

Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

Hundreds of FDA-approved drugs tested directly on a patient’s tumor sample. Could this be a gamechanger for cancer management ...

AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), a pharmaceutical giant with a market capitalization of $207.67 billion and ...

WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® ...

AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...

Morphological profiling allows accurate identification of cell types in dense iPSC-derived cultures, allowing its use for quality control and differentiation monitoring.

Individualized treatments for cancer show great promise, and three KC-area providers are dialing up their offerings.

In vivo perturbations and single-cell RNA-seq reveal cell-type-specific STAT1-IFNg signaling in regulation of trained immunity in tissue-resident immune cells.

The U.S. FDA is to temper the alert it put out in November 2023 pointing to a potential risk of CAR T therapies causing de novo malignancies. “There was this issue of possible safety concerns with T ...

Scientists have revealed the secret to the structural integrity of tiny particles that transport cargo from cell to cell ...